Search

Displaying results 5691 - 5700 of 10000 in total
  1. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973] … OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).

  2. Drug

    MK-0752

    go.drugbank.com/drugs/DB12852
    Investigational

    Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).

  3. Drug

    Camazepam

    go.drugbank.com/drugs/DB01489
    ExperimentalIllicit

    Camazepam is a benzodiazepine which is a dimethyl carbamate ester of tamzepam, a metabolite of diazepam. … In the United States camazepam is regulated as a Schedule IV controlled substance.

  4. Drug

    Contezolid

    go.drugbank.com/drugs/DB12796
    Investigational

    MRX-I has been used in trials studying the treatment of Bacterial Infections.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  5. Drug

    Bekanamycin

    go.drugbank.com/drugs/DB13673
    Investigational

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Antibacterials for Systemic Use
  6. Drug

    Cyromazine

    go.drugbank.com/drugs/DB20549
    Experimental

    Cyromazine is a small molecule drug. Cyromazine has a monoisotopic molecular weight of 166.1 Da.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    p-Phenylenediamine

    go.drugbank.com/drugs/DB14141
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  9. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in

  10. Drug

    Cariporide

    go.drugbank.com/drugs/DB06468
    Experimental